Genomic imprinting and cancer

Journal of Clinical Pathology - Molecular Pathology

Volumn 51, Issue 4, 1998, Pages 185-190

  Joyce, J A ^a   Schofield, P N ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Cancer; Chromosome 11; Genomic imprinting; Loss of imprinting; Tumour suppressor gene

Indexed keywords

CANCER; CANCER SUSCEPTIBILITY; CHROMOSOME 11Q; GENETIC SUSCEPTIBILITY; GENOME IMPRINTING; HERITABILITY; HETEROZYGOSITY LOSS; HUMAN; PRIORITY JOURNAL; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 0031874315     PISSN: 13668714     EISSN: None     Source Type: Journal    
DOI: 10.1136/mp.51.4.185     Document Type: Review

References (117)

1. Elliott M, Maher ER. Beckwith-Wiedemann syndrome. J Med Genet 1994;31:560-4.
2. Struycken, PM, Cremers CWRJ, Mariman ECM, et al. Glomus tumours and genomic imprinting: influence of inheritance along the paternal or maternal line. Clin Otolaryngol 1997;22:71-6.
3. Mariman ECM, Vanbeersum SEC, Cremers CWRJ, et al. Fine mapping of a putatively imprinted gene for familial nonchromaffin paragangliomas to chromosome 11q13.1 evidence for genetic heterogeneity. Hum Genet 1995;95:56-62.
4. Van Schothorst EM, Jansen, JC, Bardoel AFJ, et al. Confinement of PGL, an imprinted gene causing hereditary paragangliomas, to a 2cM interval on 11q22 q23 and exclusion of DRD2 and NCAM as candidate genes. Eur J Hum Genet 1996;4:267-73.
5. Baysal BE, vanSchothorst EM, Farr JE, et al. A high resolution physical map of the hereditary paraganglioma region on chromosmal band 11q23; evaluation of the candidate genes and characterisation of new polymorphisms. Am J Hum Genet 1997;61:1337.
6. Scrable H, Cavenee W, Ghavimi F, et al. A model for embryonal rhabdomyosarcoma tumorigenesis that involves genome imprinting. Proc Natl Acad Sci USA 1989;86: 7480-4.
7. Williams JC, Brown KW, Mott MG, et al. Maternal allele loss in Wilms' tumour. Lancet 1989;1:283-4.
8. Scott J, Cowell J, Robertson ME, et al. IGF-II gene expression in Wilms tumour and embryonic tissues. Nature 1985; 317:260-2.
9. Yun K, Molenaar AJ, Fiedler AM, et al. Insulin like growth factor II messenger RNA expression in Wilms tumour, nephrogenic rest and kidney. Lab Invest 1993;69:603-15.
10. Rainier S, Johnson LA, Dobry CJ, et al. Relaxation of imprinted genes in human cancer. Nature 1993;362:747-9.
11. Ogawa O, Eccles MR, Szeto J, et al. Relaxation of insulin-like growth factor II gene imprinting in Wilms' tumour. Nature 1993;362:749-51.
12. Steenman M, Rainier S, Dobry CJ, et al. Loss of imprinting of IGF2 is linked to reduced expression and abnormal methylation of H19 in Wilms tumour. Nat Genet 1994;7: 433-9.
13. Moulton T, Crenshaw T, Hao Y, et al. Epigenetic lesions at the H19 gene in Wilms tumour patients. Nat Genet 1994;7: 440-7.
14. KIP2 and its reduced expression in Wilms tumors. Hum Mol Genet 1996;5:783-8.
15. KIP2 in Wilms' tumor. Cancer Res 1996;56:5723-7.
16. Liu JQ, Kahri AI, Heikkila P, et al. Ribonucleic acid expression of the clustered imprinted genes, p57 (KIP2), insulin-like growth factor II, and H19, in adrenal tumors and cultured adrenal cells. J Clin Endocrinol Metab 1997;82:1766-71.
17. Ilvesmaki V, Kahri AI, Miettinen PJ, et al. Insulin-like growth factors (IGFs) and their receptors in adrenal tumors: high IGF-II expression in functional adrenocortical carcinomas. J Clin Endocrinol Metab 1993;77:852-88.
18. Seizinger BR, Klinger HP, Junien C, et al. Report on the commitee on chromosome and gene loss in human neoplasia. Cytogenet Cell Genet 1991;58:1080-96.
19. Gicquel C, RaffinSanson ML, Gaston V, et al. Structural and functional abnormalities at 11p15 are associated with the malignant phenotype in sporadic adrenocortical tumors: study on a series of 82 tumors. J Clin Endocrinol Metab 1997;82:2559-65.
20. Casola S, Pedone PV, Cavazzana AO, et al. Expression and parental imprinting of the H19 gene in human rhabdomyosarcoma. Oncogene 1997;14:1503-10.
21. Visser M, Sijmons C, Bras J, et al. Allelotype of pediatric rhabdomyosarcoma. Oncogene 1997;11:1309-14.
22. Zhan SL, Shapiro DN, Helman LJ. Activation of an imprinted allele of the insulin-like growth factor-II gene implicated in rhabdomyosarcoma. J Clin Invest 1994;94: 445-8.
23. Minniti CP, Tsokos M, Newton WA, et al. Specific expression of insulin-like growth factor II in rhabdomyosarcoma tumor cells. Am J Clin Pathol 1994;101:198-203.
24. Albrecht S, von Schweinitz D, Waha A, et al. Loss of maternal alleles on chromosome arm 11p in hepatoblastoma. Cancer Res 1994;54:5041-4.
25. Li X, Adam G, Cui B, et al. Expression, promoter usage and parental imprinting status of insulin-like growth factor II (IGF2) in human hepatoblastoma: uncoupling of IGF2 and H19 imprinting. Oncogene 1995;11:221-9.
26. Little MH, Thomson DB, Hayward NK. Loss of alleles on the short arm of chromosome 11 in a hepatoblastoma from a child with Beckwith-Wiedemann syndrome. Hum Genet 1988;79:186-9.
27. Ariel I, Ayesh S, Perlman EJ, et al. The product of the imprinted H19 gene is an oncofetal RNA. J Clin Pathol: Mol Pathol 1997;50:34-44.
28. De Souza AT, Hankins GR, Washington MK, et al. M6P/IGF2R gene is mutated in human hepatocellular carcinomas with loss of heterozygosity. Nat Genet 1995;11: 447-9.
29. Yamada T, DeSouza AT, Finkelstein S, et al. Loss of the gene encoding mannose 6-phosphate insulin-like growth factor II receptor is an early event in liver carcinogenesis. Proc Natl Acad Sci USA 1997;94:10351-5.
30. De Souza AT, Hankins GR, Washington MK, et al. Frequent loss of heterozygosity on 6q at the mannose 6-phosphate/insulin-like growth factor II receptor locus in human hepatocellular tumors. Oncogene 1995;10:1725-9.
31. Kim KS, Lee YI. Biallelic expression of the H19 and IGF2 genes in hepatocellular carcinoma. Cancer Lett 1997;119: 143-8.
32. Hankins GR, DeSouza AT, Bentley RC, et al. M6P/IGF2 receptor: a candidate breast tumor suppressor gene. Oncogene 1996;12:2003-9.
33. Tran YK, Newsham IF. High-density marker analysis of 11p15.5 in non-small cell lung carcinomas reveals allelic detection of one shared and one distinct region when compared to breast carcinomas. Cancer Res 1996;56:2916-21.
34. McCann AH, Miller N, O'Meara A, et al. Biallelic expression of the IGF2 gene in human breast disease. Hum Mol Genet 1996;5:1123-7.
35. Wu HK, Squire JA, Catzavelos CG, et al. Relaxation of imprinting of human insulin-like growth factor II gene, IGF2, in sporadic breast carcinomas. Biochem Biophys Res Commun 1997;235:123-9.
36. Karnik P, Paris M, Williams BRG, et al. Two distinct tumor suppressor loci within chromosome 11p15 implicated in breast cancer progression and metastasis. Hum Mol Genet 1998;7:895-908.
37. KIP2 gene at 11p15.5. Oncogene 1996;12: 1365-8.
38. Kondo M, Suzuki H, Ueda R, et al. Frequent loss of imprinting of the H19 gene is often associated with its overexpression in human lung cancers. Oncogene 1995;10: 1193-8.
39. Kondo M, Suzuki H, Ueda R, et al. Parental origin of 11p15 deletions in human lung cancer. Oncogene 1994;9:3063-5.
40. Suzuki H, Ueda R, Takahashi T, et al. Altered imprinting in lung cancer. Nat Genet 1994;6:332-3.
41. Virmani AK, Fong KM, Kodagoda D, et al. Allelotyping demonstrates common and distinct patterns of chromosomal loss in human lung cancer types. Genes Chromosomes Cancer 1998;21:308-19.
42. Ouyang H, Shiwaku HO, Hagiwara H, et al. The insulin-like growth factor II receptor gene is mutated in genetically unstable cancers of the endometrium, stomach and colorectum. Cancer Res 1997;57:1851-4.
43. Kinouchi Y, Hiwatashi N, Higashioka S, et al. Relaxation of imprinting of the insulin-like growth factor-II gene in colorectal cancer. Cancer Lett 1996;107:105-8.
44. Vu TH, Yballe C, Boonyanit S, et al. IGF-II in uterine smooth muscle tumours: maintenance of genomic imprinting in leiomyomata and loss in leiomyosarcomata. J Clin Endocrinol Metab 1995;80:849-59.
45. van Gurp RJHLM Oosterhuis JW, Kalscheuer V, et al. Biallelic expression of the H19 and IGF2 genes in human testicular germ cell tumors. J Natl Cancer Inst 1994;86:1070-5.
46. Verkerk A, Ariel I, Dekker MC, et al. Unique expression patterns of H19 in human testicular cancers of different etiology. Oncogene 1997;14:95-107.
47. Oda H, Kume H, Shimizu Y, et al. Loss of imprinting of IGF2 in renal cell carcinoma. Int J Cancer 1998;75:343-6.
48. Morito R, Saito S, Ishikawa J, et al. Common regions of deletion on chromosomes 5q,6q, and 10q in renal cell carcinoma. Cancer Res 1991;51:5817-20.
49. Sohda T, Soejima H, Matsumoto T, et al. Insulin-like growth factor 2 gene imprinting in clear cell sarcoma of the kidney. Hum Pathol 1998;28:1315-18.
50. Lustig-Yarev O, Schulze E, Komitowski D, et al. The expression of the imprinted genes H19 and IGF-2 in choriocarinoma cell lines. Is H19 a tumor suppressor gene? Oncogene 1997;15:169-77.
51. Rachmilewitz J, Elkin M, Rosensaft J, et al. H19 expression and tumorigenicity of choriocarcinoma derived cell lines. Oncogene 1995;11:863-70.
52. Hashimoto KAC, Koyama M, Ohashi K, et al. Loss of imprinting in choriocarcinoma. Nat Genet 1995;9:109-10.
53. Walsh C, Miller SJ, Flam F, et al. Paternally derived H19 is differentially expressed in malignant and nonmalignant trophoblast. Cancer Res. 1995;55:1111-16.
54. Douc-Rasy S, Barrios M, Fogel S, et al. High incidence of loss of heterozygosity and abnormal imprinting of H19 and IGF2 genes in invasive cervical carcinomas. Uncoupling of H19 and IGF2 expression and biallelic hypomethylation of H19. Oncogene 1996;12:423-30.
55. Muliokandov MR, Kholodilov MG, Atkin NB, et al. Genomic alterations in cervical carcinoma losses of chromosome heterozygosity and human papilloma virus tumor status. Cancer Res 1996;56:197-205.
56. Hibi K, Nakamura H, Hirai A, et al. Loss of H19 imprinting in esophageal cancer. Cancer Res 1996;56:480-2.
57. Mori M, Inoue H, Shiraishi T, et al. Relaxation of insulin-like growth factor 2 gene imprinting in esophageal cancer. Int J Cancer 1996;68:441-6.
58. Cooper MJ, Ficher M, Komitowski D, et al. Developmentally imprinted genes as markers for bladder tumor progression. J Urol 1996;155:2120-7.
59. Wu HK, Weksberg R, Minden MD, et al. Loss of imprinting of human insulin-like growth factor II gene, IGF2, in acute myeloid leukemia. Biochem Biophys Res Common 1997;231: 466-72.
60. Souza RF, Appel R, Yin J, et al. Microsatellite instability in the insulin-like growth factor II receptor in gastrointestinal tumors. Nat Genet 1997;14:255-7.
61. Wu MS, Wang HP, Lin CC, et al. Loss of imprinting and overexpression of IGF2 gene in gastric adenocarcinoma. Cancer Lett 1997;120:9-14.
62. Queimado L, Seruca R, Costapereira A, et al. Identification of 2 distinct regions of deletion at 6q in gastric carcinoma. Genes Chromosomes Cancer 1995;14:28-34.
63. Debiecrychter M, Alwasiak J, Liberski PP, et al. Accumulation of chromosomal changes in human glioma progression - a cytogenetic study of 50 cases. Cancer Genet Cytogenet 1997;75:1831-5.
64. Uyeno S, Aoki Y, Nata M, et al. IGF2 but not H19 shows loss of imprinting in human glioma. Cancer Res 1996;56: 5356-9.
65. Saito S, Salto H, Koi S, et al. Fine-scale deletion mapping of the distal long arm of chromosome 6 in 70 human ovarian cancers. Cancer Res 1992;52:5815-17.
66. Yun K, Fukumoto M, Jinno Y. Monoallelic expression of the insulin-like growth factor-II gene in ovarian-cancer. Am J Pathol 1996;148:1081-7.
67. Wada M, Seeger RC, Mizoguchi H. Maintenance of normal imprinting of H19 and IGF2 genes in neuroblastoma. Cancer Res 1995;55:3386-8.
68. Knudsen AG, Strong LC. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 1971;68: 820-3.
69. Howdy, SF, Fasching, CL, Araujo D, et al. Suppression of tumourigenicity in Wilms' tumour by the p15.5 p14 region of chromosome 11. Science 1991;254:293-5.
70. Koi MJL, Kalikin LM, Little PFR, et al. Tumor cell growth arrest caused by subchromosomal transferable DNA fragments from chromosome 11. Science 1993;260:361-4.
71. Reid LH, West A, Gioeli DG, et al. Localisation of a tumour suppressor gene in 11p15.5 using the G401 Wilms' tumour cell assay. Hum Mol Genet 1996;5:239-47.
72. Werner H, LeRoith D. The role of the insulin-like growth factor system in human cancer. Adv Cancer Res 1996;68: 183-223.
73. Rubin R, Baserga R. IGF-I receptor. Lab Invest 1995;73: 311-31.
74. Ogawa O, Mc Noe LA, Eccles MR, et al. Human insulin-like growth factor type I and type II receptors are not imprinted. Hum Mol Genet 1993;2:2163-5.
75. Sell C, Rubini M, Rubin R, et al. Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type I insulin-like growth factor receptor. Proc Natl Acad Sci USA 1993;90:11217-21.
76. Schofield PN. The IGFs in cell growth and transformation. In: Gorin N, ed. Education programme of the European haematology association. Oxford: Blackwell, 1996:112-17.
77. Christofori G, Naik P, Hanahan D. A second signal supplied by insulin-like growth factor II in oncogene-induced tumorigenesis. Nature 1994;369:414-18.
78. DeChiara TM, Robertson EJ, Efstratiadis A. Parental imprinting of the mouse insulin-like growth factor II gene. Cell 1991;64:849-59.
79. Ohlsson R, Nystrom A, Pfeifer-Ohlsson S, et al. IGF2 is parentally imprinted during human embrogenesis and in the Beckwith Wiedemann syndrome. Nat Genet 1993;4:94-7.
80. Giannoukakis N, Deal C, Paquette J, et al. Parental genomic imprinting of the human IGF2 gene. Nat Genet 1993;4:98-101.
81. Taniguchi T, Sullivan MJ, Ogawa O, et al. Epigenetic changes encompassing the IGF2/H19 locus associated with relaxation of IGF2 imprinting and silencing of H19 in Wilms tumor. Proc Natl Acad Sci USA 1995;92:2159-63.
82. Weksberg R, Shen DR, Fei YL, et al. Disruption of insulin-like growth factor 2 imprinting in Beckwith-Wiedemann syndrome. Nat Genet 1993;5:143-50.
83. Joyce JA, Lam WK, Catchpoole DJ, et al. Imprinting of IGF2 and H19: lack of reciprocity in sporadic Beckwith Wiedemann syndrome. Hum Mol Genet 1997;6:1543-8.
84. Wang WH, Duan JX, Vu TH, et al. Increased expression of the insulin-like growth factor II gene in Wilms' tumor is not dependent on loss of genomic imprinting or loss of heterozygosity. J Biol Chem 1996;271:27863-70.
85. Davies S. Maintenance of genomic imprinting at the IGF2 locus in hepatoblastoma. Cancer Res 1993;53:4781-3.
86. Zhan S, Shapiro DN, Helman LJ. Loss of imprinting of IGF2 in Ewing's sarcoma. Oncogene 1995;11:2503-7.
87. Pedone PV, Tirabosco R, Cavazzana AO et al. Mono- and bi-allelic expression of insulin-like growth factor II in human muscle tumors. Hum Mol Genet 1994;3:1117-21.
88. Gloudemans T, Prinsen I, Vannounik JAM, et al. Insulin-like growth factor gene expression in human smooth muscle tumors. Cancer Res 1990;50:6689-95
89. Zhang Y, Tycko B. Monoallelic expression of the human H19 gene. Nat Genet 1992;1:40-4.
90. Hao Y, Crenshaw T, Moulton T, et al. Tumour-suppressor activity of H19 RNA. Nature 1993;365:764-7.
91. Brannan CI, Dees EC, Ingram RS, et al. The product of the H19 gene may function as an RNA. Mol Cell Biol 1990;10: 28-36.
92. Bartolomei MS, Webber AL, Brunkow ME, et al. Epigenetic mechanisms underlying the imprinting of the mouse H19 gene. Genes Dev 1993;7:1663-73.
93. KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev 1995;9:639-49.
94. KIP2, a structurally distinct member of the p21CIPI CDK inhibitor family, is a candidate tumor suppressor gene. Genes Dev 1995;9: 650-662.
95. KIP2, a cyclin dependent kinase inhibitor in mouse. Nat Genet 1995;11: 204-6.
96. Cost GJ, Thompson JS, Reichard BA, et al. Lack of imprinting of three human cyclin-dependent kinase inhibitor genes. Cancer Res 1997;57:926-9.
97. KIP2 requires binding to proliferating cell nuclear antigen. Proc Natl Acad Sci USA 1998;95:1392-7.
98. KIP2 is expressed in Wilms' tumor with LOH of 11p15.5. Genes Chromosomes Cancer 1996;17:56-9.
99. KIP2 in soft-tissue sarcomas and Wilms' tumors. Cancer Res 1996;56:1219-21.
100. KIP2 gene - alternative splicing, insertion deletion polymorphisms in VNTR sequences in the coding region, and mutational analysis. Hum Genet 1996;97:625-31.
101. KIP2 genes in hepatocellular carcinoma. Int J Oncol 1998;12:583-8.
102. KIP2 is mutated in Beckwith-Wiedemann syndrome. Nat Genet 1996;14:171-3.
103. KIP2 are present in some cases Beckwith-Wiedemann syndrome but are rare or absent in Wilms' tumors. Am J Hum Genet 1997;61:295-303.
104. KIP2 mutation in Beckwith-Wiedemann syndrome. Am J Hum Genet 1997;61:304-9.
105. KIP2 gene and its analysis in the G401 Wilms' tumor assay. Cancer Res 1996;56:1214-18.
106. Qian N, Frank D, O'Keefe D, et al. The IPL gene on chromosome 11p15.5 is imprinted in humans and mice and is similar to TDAG51, implicated in Fas expression and apoptosis. Hum Mol Genet 1997;6:2021-9.
107. Lee MP, Feinberg AP. Genomic imprinting of a human apoptosis gene homologue, TSSC3. Cancer Res 1998;58: 1052-6.
108. Schweinbacher C, Sabbioni S, Campi M, et al. Transcriptional map of 170-kb region at chromosome 11p15.5: identification and mutational analysis of the BWR1A gene reveals the presence of mutations in tumor samples. Proc Natl Acad Sci USA 1998;95:3873-8.
109. Sabbioni S, Barbanti-Brodano G, Croce CM, et al. GOK: a gene at 11p15 involved in rhabdomyosarcoma and rhabdoid tumor development. Cancer Res 1997;60:4493-7.
110. Horsthemke B. Structure and function of the human chromosome 15 imprinting center. J Cell Physiol 1997;173:237-41.
111. Barlow DP, Stoger R, Herrmann BG, et al. The mouse insulin-like growth-factor type-2 receptor is imprinted and closely linked to the Tme locus. Nature 1991;349:84-7.
112. Xu YQ, Goodyer CG, Deal C, et al. Functional polymorphism in the parental imprinting of the human 1GF2R gene. Biochem Biophys Res Commun 1993;197:747-54.
113. Lau MMH, Stewart CEH, Lui ZY, et al. Loss of the imprinted IGF2/cation-independent mannose 6-phosphate receptor results in fetal overgrowth and perinatal lethality. Genes Dev 1994;8:2953-63.
114. de Bleser PJ, Jannes P, van Buul-Offeres SC, et al. Insulin-like growth factor-II/mannose 6-phosphate receptor is expressed on CCl,-exposed rat fat storing cells and facilitates activation of latent transforming grouth factor-beta in cocultures with simisoidal endothelial cells. Hepatology 1995;21:1429-37.
115. Wang K, Souza RF, Kong D, et al. Deficient transforming growth factor-β1 activation and excessive insulin-like growth factor II (IGFII) expression in IGFII receptor-mutant tumors. Cancer Res 1997;57:2543-6.
116. Jinno Y, Yun K, Nishiwaki K, et al. Mosaic and polymorphic imprintins of the WT1 gene in humans. Nat Genet 1994;6:305-9.
117. XuYQ, Grundy P, Polychronakos C. Aberrant imprinting of the insulin-like growth factor II receptor gene in W ilms' tumor. Oncogene 1997;14:1041 6.